Lanean...
Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yes
Nab-paclitaxel is a novel therapeutic agent, which was approved in combination with carboplatin in the first-line treatment of advanced non-small cell lung cancer (NSCLC) regardless of histologic subtype in the United States of America by the Food and Drug Administration in 2012 and by the European...
Gorde:
| Argitaratua izan da: | Eur J Cancer |
|---|---|
| Egile Nagusiak: | , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2016
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4844000/ https://ncbi.nlm.nih.gov/pubmed/26875112 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2015.12.022 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|